Skip to main content
SpringerLink
Log in

Screening for Neuroblastoma

  • Chapter
Advances in Cancer Screening

Part of the book series: Cancer Treatment and Research ((CTAR,volume 86))

Abstract

Screening for a malignant disease is an attempt to find an asymptomatic and curable disease before it develops into one that is both symptomatic and incurable. The success of such a venture depends upon the sensitivity and specificity of the screening tool used, the extent to which the target population participates in the screening program, the ease with which the asymptomatic disease may be cured, and the likelihood that the asymptomatic disease will progress into an advanced-stage malignancy. Neuroblastoma is likely to be the only pediatric malignancy subject to a screening trial, since the tumor commonly secretes chemicals that can be detected in urine, the disease is of relatively high frequency (exceeded only by hypothyroidism among diseases currently screened for in the early newborn period), and, when present in advanced form in older infants, it is a disease that is extremely difficult to cure.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bernstein ML, Leclerc JM, Bunin G, et al. 1992. A population based study of neuroblastoma incidence, survival, and mortality in North America. J Clin Oncol 10:323–329.

    PubMed  CAS  Google Scholar 

  2. Beckwith JB, Perrin EV. 1963. In situ neuroblastomas: a contribution to the natural history of neural crest tumours. Am J Pathol 43:1089–1104.

    PubMed  CAS  Google Scholar 

  3. Turkel SB, Itabashi HH. 1974. The natural history of neuroblastoma cells in the fetal adrenal gland. Am J Pathol 76:225–244.

    PubMed  CAS  Google Scholar 

  4. Brodeur GM, Hayes FA, Green AA, et al. 1987. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients. Cancer Res 47:4248–4253.

    PubMed  CAS  Google Scholar 

  5. Taylor SR, Blatt J, Costantino JP, et al. 1988. Flow cytometric DNA analysis of neuroblastoma and ganglioneuroma. Cancer 62:749–754.

    Article  PubMed  CAS  Google Scholar 

  6. Brodeur GM, Castleberry RP. 1993. Neuroblastoma. In Pizzo PA, Poplack DG (eds.), Principles and Practice of Pediatric Oncology, 2nd edition, Philadelphia: J.B. Lippincott, pp. 739–768.

    Google Scholar 

  7. Matthay KM. 1994. Neuroblastoma. In Pochedly C (ed.), Neoplastic Diseases of Childhood. Basel: Harwood Academic Publishers, pp. 735–778.

    Google Scholar 

  8. Philip T, Zucker JM, Bernard JL, et al. 1991. Improved survival at 2 and 5 years in the LMCE 1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: Is cure possible in a small subgroup? J Clin Oncol 9:1045–1049.

    Google Scholar 

  9. Tuchman M, Morris CL, Ramnaraine ML, et al. 1985. Value of random urinary homovanillic acid and vanillylmandelic acid levels in the diagnosis and management of patients with neuroblastoma: Comparison with 24-hour urine collections. Pediatrics 75:324–328.

    PubMed  CAS  Google Scholar 

  10. Tuchman M, Ramnaraine MLR, Woods WG, Krivit W. 1987. Three years of experience with random urinary homovanillic and vanillylmandelic acid levels in the diagnosis of neuroblastoma. Pediatrics 79:203–205.

    PubMed  CAS  Google Scholar 

  11. Tuchman M, Robison LL, Maynard RC, et al. 1985. Assessment of the diurnal variations in urinary homovanillic and vanillylmandelic acid excretion for the diagnosis and follow-up of patients with neuroblastoma. Clin Biochem 18:176–179.

    Article  PubMed  CAS  Google Scholar 

  12. Tuchman M, Auray-Blais C, Ramnaraine MLR, et al. 1987. Determination of urinary homovanillic and vanillylmandelic acids from dried filter paper samples: assessment of potential methods for neuroblastoma screening. Clin Biochem 20:173–177.

    Article  PubMed  CAS  Google Scholar 

  13. Sawada T, Todo S, Fujita K, et al. 1982. Mass screening of neuroblastoma in infancy. Am J Dis Child 136:710–712.

    PubMed  CAS  Google Scholar 

  14. Sawada T, Nakata T, Takasugi N, et al. 1984. Mass screening for neuroblastoma in infants in Japan: interim report of a mass screening study group. Lancet ii:271–273.

    Article  Google Scholar 

  15. Nishi M, Miyake H, Takeda T, et al. 1987. Effects of the mass screening of neuroblastoma in Sapporo City. Cancer 60:433–436.

    Article  PubMed  CAS  Google Scholar 

  16. Goodman SN. 1991. Neuroblastoma screening data: an epidemiologic analysis. Am J Dis Child 145:1415–1422.

    PubMed  CAS  Google Scholar 

  17. Craft AW, Parker L. 1992. Poor prognosis neuroblastoma: is screening the answer? Br J Cancer 66 (Suppl XVIII):S96-S101.

    Google Scholar 

  18. Lemieux B, Auray-Blais C, Giguere R, et al. 1988. Newborn urine screening experience with over one million infants in the Quebec Network of Genetic Medicine. J Inher Metab Dis 11:45–55.

    Article  PubMed  CAS  Google Scholar 

  19. Scriver C, Gregory D, Bernstein M, et al. 1987. Feasibility of chemical screening of urine for neuroblastoma case finding in infancy in Quebec. Can Med Assoc J 136:952–956.

    CAS  Google Scholar 

  20. Auray-Blais C, Giguere R, Lemieux B. 1989. Thin-layer chromatography of urinary homovanillic acid and vanillylmandelic acid for large-scale neuroblastoma mass screening. Med Pediatr Oncol 17:364–367.

    Article  PubMed  CAS  Google Scholar 

  21. Tuchman M, Crippin PJ, Krivit W. 1983. Capillary gas-chromatographic determination of urinary homovanillic acid and vanillylmandelic acid. Clin Chem 29:828–831.

    PubMed  CAS  Google Scholar 

  22. Davis S, Rogers MAM, Pendergrass TW. 1987. The incidence and epidemiologic characteristics of neuroblastoma in the United States. Am J Epidemiol 126:1063–1074.

    PubMed  CAS  Google Scholar 

  23. Monobe Y, Takeuchi LA, Hachitanda Y, et al. 1995. Pathology review for neuroblastoma mass screening program in North America: a report from the Quebec Project. Submitted for presentation, Society for Pediatric Pathology.

    Google Scholar 

  24. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al. 1993. Association between high levels of expression of the TRK gene and favorable outcome in neuroblastoma. N Engl J Med 328:847–854.

    Article  PubMed  CAS  Google Scholar 

  25. Vogan KJ, Bernstein ML, Brisson L, et al. 1993. Absence of p53 mutations in primary neuroblastoma. Cancer Res 53:5269–5273.

    PubMed  CAS  Google Scholar 

  26. Bessho F, Hashizume K, Nakajo T, Kamoshita S. 1991. Mass screening in Japan increased the detection of infants with neuroblastoma without a decrease in cases in older children. J Pediatr 119:237–241.

    Article  PubMed  CAS  Google Scholar 

  27. Hayashi Y, Hanada R, Yamamoto K. 1992. Biology of neuroblastomas in Japan found by screening. Am J Pediatr Hematol Oncol 14:342–347.

    Article  PubMed  CAS  Google Scholar 

  28. Nakagawara A, Zaizen Y, Ikeda K, et al. 1991. Different genomic and metabolic patterns between mass screening-positive and mass screening-negative later-presenting neuroblastomas. Cancer 68:2037–2044.

    Article  PubMed  CAS  Google Scholar 

  29. Hachitanda Y, Ishimoto K, Hata J, Shimada H. 1994. One hundred neuroblastomas detected through a mass screening system in Japan. Cancer 74:3223–3226.

    Article  PubMed  CAS  Google Scholar 

  30. Ishimoto K, Kiyokawa N, Fujita H, et al. 1990. Problems of mass screening for neuroblastoma: analysis of false-negative cases. J Pediatr Surg 25:398–401.

    Article  PubMed  CAS  Google Scholar 

  31. Suita S, Zaizen Y, Yano H, et al. 1994. How to deal with advanced cases of neuroblastoma detected by mass screening: a report from the Pediatric Oncology Study Group of the Kyushu area of Japan. J Pediatr Surg 29:599–603.

    Article  PubMed  CAS  Google Scholar 

  32. Nishi M, Miyake H, Takeda T, et al. 1994. A trial to discriminate spontaneous regression from non-regression cases during mass screening for neuroblastoma. Jpn J Clin Oncol 24:247–251.

    PubMed  CAS  Google Scholar 

  33. Hanawa Y, Sawada T, Tsunoda A. 1990. Decrease in childhood neuroblastoma death in Japan. Med Pediatr Oncol 18:472–475.

    Article  PubMed  CAS  Google Scholar 

  34. Hanawa Y. 1993. The recent trend of childhood neuroblastoma death in Japan. Presented at the Third International Symposium on Neuroblastoma Screening, Kyoto, Japan.

    Google Scholar 

  35. Cole M, Parker L, Craft A. 1993. Decrease in childhood neuroblastoma death in Japan (letter to the editor). Med Pediatr Oncol 20:84–85.

    Article  Google Scholar 

  36. Huddart SN, Muir KR, Parkes S, et al. 1993. Neuroblastoma: a 32-year population-based study — implications for screening. Med Pediatr Oncol 21:96–102.

    Article  PubMed  CAS  Google Scholar 

  37. Sankila R, Hakama M. 1992. Survival trends for neuroblastoma patients in Finland: negative reflections on screening. Eur J Cancer 29A:122–123.

    PubMed  CAS  Google Scholar 

  38. Parker L, Craft AW, Dale G, et al. 1992. Screening for neuroblastoma in the north of England. Br J Med 305:1260–1263.

    Article  CAS  Google Scholar 

  39. Mathieu P, Favrot M, Frappaz D, et al. 1993. Le neuroblastome de l’enfant: aspects cliniques et biologiques. Une experience de depistage en France. Ann Biol Clin 51:665–688.

    CAS  Google Scholar 

  40. Schilling FH, Erttmann, Ambros PF, et al. 1994. Neuroblastoma with unfavourable prognostic parameters detected by mass screening: report of the German pilot study. Proc Am Soc Clin Oncol 13:421 (#1440).

    Google Scholar 

  41. Tuchman M, Fisher EJ, Heisel MA, Woods WG. 1989. Feasibility study for neonatal neuroblastoma screening in the United States. Med Pediatr Oncol 17:258–264.

    Article  PubMed  CAS  Google Scholar 

  42. Woods WG, Lemieux B, Tuchman M. 1992. Neuroblastoma represents distinct clinical-biologic entities: a review and perspective from the Quebec Neuroblastoma Screening Project. Pediatrics 89:114–118.

    PubMed  CAS  Google Scholar 

  43. Esteve J. 1993. Some remarks on power calculation for neuroblastoma screening. Presented at the Third International Symposium on Neuroblastoma Screening, Kyoto, Japan.

    Google Scholar 

  44. Murphy SB, Cohn SL, Craft AW, et al. 1991. Do children benefit from mass screening for neuroblastoma? Consensus statement from the American Cancer Society Workshop on Neuroblastoma Screening. Lancet 337:344–346.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Mark L. Bernstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William G. Woods
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Toronto, Canada

    Anthony B. Miller

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Kluwer Academic Publishers

About this chapter

Cite this chapter

Bernstein, M.L., Woods, W.G. (1996). Screening for Neuroblastoma. In: Miller, A.B. (eds) Advances in Cancer Screening. Cancer Treatment and Research, vol 86. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1265-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1265-9_11

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8539-7

  • Online ISBN: 978-1-4613-1265-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation